Health City recently announced a unique collaboration with Boehringer Ingelheim (Canada) Ltd – a collaboration that includes clinicians (physicians) and local companies.
“Our mandate is to drive economic development through innovation in the health sector in this region and this project is the first example of the kind of model we believe will do that,” says Health City CEO, Reg Joseph.
“We’re excited that our partnership with Boehringer Ingelheim allows us to bring together this collaborative team from our vibrant health community to solve this very real challenge for our senior’s population, locally and nationally.” Source: Health City
The goal is to enable healthcare teams to proactively identify patients who could benefit from more individualized care and evidence-based interventions such as fall prevention, medication review, or social service interventions to help further mitigate frailty. At the heart of the project is the development of a tool that can facilitate how front-line providers are able to identify patients earlier in order to provide appropriate patient-centred interventions to support healthy aging. Source: Health City
“Frailty is the most concerning reality of our aging population.1 ” It is estimated that approximately 1 in 4 older adults are at imminent risk of becoming frail and are at a greater risk for declining health, higher health care utilization, and loss of independence.2 ” However, if frailty and risk for chronic disease can be identified earlier, there is an opportunity to intervene and improve care pathways for patients and positively impact their health. Source: Health City Ref: (See Below)
The advancement of technologies to analyze and correlate data through artificial intelligence (AI) provides an opportunity for Health City to collaborate with organizations and companies towards attaining a future goal of preventing the onset of chronic diseases. Specifically this project will leverage AI to examine data as a means to better predict frailty and its impact on chronic diseases such as heart disease and diabetes.
So why did they join the project and what value will the project impact have on health in communities – regionally and nationally?
https://www.youtube.com/edit?ar=2&o=U&video_id=f59bYbVxOB4
Futurecite features in this video, additional insights on the shared vision from the perspective of collaborating organizations and companies: a brief podium overview from Mayor Don Iverson, City of Edmonton, and one-on-one video interviews from behind the scenes with Reg Joseph CEO of Health City, Dr. Uli Broedl VP of Boehringer Ingelheim, Jason Pincock, CEO Dynalife Labs, and Cory Janssen CEO of AltaML.
About Boehringer Ingelheim (Canada) Ltd.
Improving the health and quality of life of patients is the goal of Boehringer Ingelheim, a research-driven pharmaceutical company. In doing so, the focus is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention.
Family-owned since it was established in 1885, Boehringer Ingelheim is one of the top 20 companies in the pharmaceutical industry. Some 50,000 employees create value through innovation daily for the three business areas: human pharmaceuticals, animal health and biopharmaceuticals. In 2017, Boehringer Ingelheim achieved net sales of nearly 18.1 billion euros. Research and development expenditure, exceeding three billion euros, corresponded to 17.0 per cent of net sales.
As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success, rather than short-term profit. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment.
The Canadian headquarters of Boehringer Ingelheim was established in 1972 in Montreal, Quebec and is now located in Burlington, Ontario. Boehringer Ingelheim employs approximately 600 people across Canada.
About Health City
Health City is an economic development organization created to catalyze and accelerate health innovation in Edmonton – transforming innovations from our region into solutions that have commercial application and global relevance. Health City’s role is to form innovation consortiums, bringing together highly talented people and organizations to enable innovation and products to get to market. Health City serves as a central connection point for Edmonton’s health innovation sector; working with and seeking inspired partners who share a vision for excellence, have a culture of collaboration and who are driven to take health innovation to the next level.
About AltaML
AltaML builds transformational software for business, powered by machine learning (ML) – partnering with organizations using a co-development model where we can provide technical and strategic expertise on how to leverage their data with AI/ML to deliver significant ROI and new forms of competitive advantage.
Sources: Health City Ref:
1.Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly people. The Lancet. 2013;381(9868):752–62. Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly people. The Lancet. 2013;381(9868):752–62.
2.Song X, Mitnitski A, Rockwood K. Prevalence and 10‐year outcomes of frailty in older adults in relation to deficit accumulation. J Am Geriatr Soc. 2010;58(4):681–7. Rockwood K, Fox RA, Stolee P, Robertson D, Beattie BL. Frailty in elderly people: an evolving concept. CMAJ Can Med Assoc J. 1994;150(4):489–495.
